Compare Johnson & Johnson (JNJ) vs Visa Inc (V) Price & Performance

Johnson & Johnson (JNJ) trades at $249.58, down 1.37% today, amid a generally bullish technical outlook with strong moving average signals. The company reported robust Q2 2026 earnings, beating EPS estimates and raising full-year guidance, with revenue growth to $94.19B in 2025 and a net income margin of 21.48%. Recent news highlights strong institutional interest and positive analyst sentiment, though the stock faces pressure from MedTech segment misses despite overall strength.

The outlook for JNJ remains positive, supported by solid fundamentals, a consistent dividend history, and upward revised earnings guidance. Key risks include competitive pressures in pharmaceuticals, regulatory hurdles, and execution challenges in the MedTech division. With a consensus price target of $279.33, representing ~12% upside, the stock offers a compelling opportunity for long-term investors, balanced by sector-specific volatility and macroeconomic factors.

Visa (V) trades at $357.76, down 0.22% on the day, with a bullish technical signal and strong analyst consensus. The stock shows robust fundamentals with Q1 2026 EPS beating estimates at $3.31 versus $3.10 expected, and revenue growth from $35.9B in 2024 to $40B in 2025. Recent news highlights Visa's AI initiatives, including Intelligent Commerce Connect, to enhance payment efficiency.

Outlook remains positive with an average price target of $396.70, implying 11% upside. Risks include competitive threats from fintech and stablecoins, as noted by The Motley Fool on April 10, 2026. Strong cash flow and high net income margin of 51.68% support long-term growth, but regulatory pressures could impact valuation.